Geode Capital Management LLC Has $5.32 Million Position in Omeros Co. (NASDAQ:OMER)

Geode Capital Management LLC boosted its position in shares of Omeros Co. (NASDAQ:OMER) by 0.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,339,251 shares of the biopharmaceutical company’s stock after buying an additional 6,839 shares during the quarter. Geode Capital Management LLC owned approximately 2.31% of Omeros worth $5,318,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of OMER. Barclays PLC raised its holdings in Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares during the last quarter. MML Investors Services LLC grew its position in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the period. Jane Street Group LLC raised its stake in shares of Omeros by 15.9% during the third quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 8,010 shares during the last quarter. Wellington Management Group LLP acquired a new position in Omeros in the third quarter valued at approximately $305,000. Finally, State Street Corp boosted its stake in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after acquiring an additional 3,839 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on OMER shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw assumed coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Finally, StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 13.9 %

Shares of OMER stock opened at $11.21 on Friday. The company has a market capitalization of $649.62 million, a price-to-earnings ratio of -4.85 and a beta of 1.97. Omeros Co. has a 12-month low of $2.61 and a 12-month high of $13.60. The firm has a fifty day moving average of $8.32 and a 200-day moving average of $5.62.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.